[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605386":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":28,"locations":34,"responsibleParty":48,"collaborators":27,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":27,"studyType":66,"phases":67,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":77,"whyStopped":27,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Neukidney Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Use of QRX-3 in addition to standard therapy","EXPERIMENTAL","QRX-3 drug orally as twice daily in addition to standard conventional therapy will be given to this group for 28 days",[13],"Drug: QRX-3",{"label":15,"type":16,"description":17,"interventionNames":18},"control group","PLACEBO_COMPARATOR","placebo twice daily will be given to this group in addition to standard therapy",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","QRX-3","Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo",[9,15],[26],"Eseronate",null,[29],{"name":30,"role":31,"phone":32,"phoneExt":27,"email":33},"Ebima Okundaye, MD","CONTACT","9738855457","cliffordebima@gmail.com",[35],{"facility":36,"status":27,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":27},"Neukidney Inc","Rosharon","Texas","77583","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-95.46022,29.35218,{"lat":46,"lon":45},{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"SPONSOR_INVESTIGATOR","Ebima Clifford Okundaye","President","100605386","phase-2-use-of-qrx3-for-acute-tubular-necrosis-type-of-renal-failure-in-hospitalized-patients--qrx-3-in-arf-100605386",false,"NCT07161843","Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)","Determine the Efficacy of Investigational Drug QRX-3 in Hospitalized Patients With Acute Tubular Necrosis Pattern of Acute Renal Failure","QRX3 in ARF","Inclusion Criteria:\n\n* Hospitalized patients\n* presence of Acute renal failure\n* Nephrologist diagnosis of Acute tubular necrosis or fractional excretion of sodium of \\>2%\n* willingness to participate\n\nExclusion Criteria:\n\nHigh risk of bleeding Absence of hydronephrosis or obstructive uropathy Absence of baseline dialysis use single kidney status","ALL","10 Years","80 Years",{"count":64,"type":65},500,"ESTIMATED","INTERVENTIONAL",[68,69],"PHASE2","PHASE3","Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure",[72,73],"Acute Renal Failure (ARF)","Acute Tubular Necrosis",[75,76],"acute renal failure","acute tubular necrosis","NOT_YET_RECRUITING","2026-02-12",{"date":80,"type":81},"2026-02-18","ACTUAL",{"date":83,"type":65},"2026-06-30",{"date":85,"type":65},"2027-02-01",{"name":50,"class":6},1]